Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 253

1.

Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry.

Kocakova I, Melichar B, Kocak I, Bortlicek Z, Büchler T, Dusek L, Petruzelka L, Kohoutek M, Prausová J, Finek J, Mohelnikova-Duchonova B, Vyzula R.

Anticancer Res. 2015 Jun;35(6):3455-61.

PMID:
26026110
2.

Evaluation of HER2 Gene Status in Breast Cancer Samples with Indeterminate Fluorescence in Situ Hybridization by Quantitative Real-Time PCR.

Koudelakova V, Berkovcova J, Trojanec R, Vrbkova J, Radova L, Ehrmann J, Kolar Z, Melichar B, Hajduch M.

J Mol Diagn. 2015 Jul;17(4):446-55. doi: 10.1016/j.jmoldx.2015.03.007. Epub 2015 May 5.

PMID:
25956448
3.

Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study.

Kubackova K, Melichar B, Bortlicek Z, Pavlik T, Poprach A, Svoboda M, Lakomy R, Vyzula R, Kiss I, Dusek L, Prausova J, Buchler T; Czech Renal Cancer Cooperative Group.

Target Oncol. 2015 Apr 23. [Epub ahead of print]

PMID:
25903462
4.

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.

Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G Jr, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE; LUX-H&N 1 investigators.

Lancet Oncol. 2015 May;16(5):583-94. doi: 10.1016/S1470-2045(15)70124-5. Epub 2015 Apr 16.

PMID:
25892145
5.

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view.

Bencsikova B, Bortlicek Z, Halamkova J, Ostrizkova L, Kiss I, Melichar B, Pavlik T, Dusek L, Valik D, Vyzula R, Zdrazilova-Dubska L.

BMC Gastroenterol. 2015 Mar 24;15:37. doi: 10.1186/s12876-015-0266-6.

6.

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.

Deplanque G, Demarchi M, Hebbar M, Flynn P, Melichar B, Atkins J, Nowara E, Moyé L, Piquemal D, Ritter D, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Hammel P.

Ann Oncol. 2015 Jun;26(6):1194-200. doi: 10.1093/annonc/mdv133. Epub 2015 Apr 9.

PMID:
25858497
7.

RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma.

Ravaud A, Barrios CH, Alekseev B, Tay MH, Agarwala SS, Yalcin S, Lin CC, Roman L, Shkolnik M, Anak O, Gogov S, Pelov D, Louveau AL, Melichar B.

Ann Oncol. 2015 Jul;26(7):1378-84. doi: 10.1093/annonc/mdv170. Epub 2015 Apr 7.

PMID:
25851632
8.

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study.

Melichar B, Adenis A, Lockhart AC, Bennouna J, Dees EC, Kayaleh O, Obermannova R, DeMichele A, Zatloukal P, Zhang B, Ullmann CD, Schusterbauer C.

Lancet Oncol. 2015 Apr;16(4):395-405. doi: 10.1016/S1470-2045(15)70051-3. Epub 2015 Feb 27.

PMID:
25728526
9.

The highs and lows of tumor biomarkers: lost illusions.

Melichar B.

Clin Chem Lab Med. 2015 Feb;53(3):343-7. doi: 10.1515/cclm-2015-0014. No abstract available.

PMID:
25720127
10.

Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma.

Rini BI, Melichar B, Fishman MN, Oya M, Pithavala YK, Chen Y, Bair AH, Grünwald V.

Ann Oncol. 2015 Jul;26(7):1372-7. doi: 10.1093/annonc/mdv103. Epub 2015 Feb 20.

PMID:
25701454
11.

Brain metastases of parathyroid carcinoma: Review of the literature and a case report.

Studentova H, Melichar B, Cincibuch J, Kaminek M, Frysak Z, Geierova M, Klein J.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Feb 10. doi: 10.5507/bp.2015.001. [Epub ahead of print]

12.

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.

Fuchs CS, Azevedo S, Okusaka T, Van Laethem JL, Lipton LR, Riess H, Szczylik C, Moore MJ, Peeters M, Bodoky G, Ikeda M, Melichar B, Nemecek R, Ohkawa S, Świeboda-Sadlej A, Tjulandin SA, Van Cutsem E, Loberg R, Haddad V, Gansert JL, Bach BA, Carrato A.

Ann Oncol. 2015 May;26(5):921-7. doi: 10.1093/annonc/mdv027. Epub 2015 Jan 21.

PMID:
25609246
13.

Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency.

Poprach A, Bortlicek Z, Melichar B, Lakomy R, Svoboda M, Kiss I, Zemanova M, Fiala O, Kubackova K, Coufal O, Pavlik T, Dusek L, Vyzula R, Buchler T.

Eur J Cancer. 2015 Mar;51(4):507-13. doi: 10.1016/j.ejca.2014.12.010. Epub 2015 Jan 7.

PMID:
25577735
14.

Cancer incidence and mortality in the Czech Republic.

Dusek L, Muzik J, Maluskova D, Májek O, Pavlík T, Koptíková J, Melichar B, Büchler T, Fínek J, Cibula D, Babjuk M, Svoboda M, Vyzula R, Ryska A, Ryska M, Petera J, Abrahámová J.

Klin Onkol. 2014;27(6):406-23.

PMID:
25493580
15.

Hepatic arterial infusion in hepatocellular carcinoma: a single center experience.

Melichar B, Dvorak J, Ferko A, Kamaradova K, Krajina A.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Mar;159(1):139-44. doi: 10.5507/bp.2014.054. Epub 2014 Nov 11.

16.

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study.

Jackisch C, Kim SB, Semiglazov V, Melichar B, Pivot X, Hillenbach C, Stroyakovskiy D, Lum BL, Elliott R, Weber HA, Ismael G.

Ann Oncol. 2015 Feb;26(2):320-5. doi: 10.1093/annonc/mdu524. Epub 2014 Nov 17.

PMID:
25403587
17.

Determination of lipidomic differences between human breast cancer and surrounding normal tissues using HILIC-HPLC/ESI-MS and multivariate data analysis.

Cífková E, Holčapek M, Lísa M, Vrána D, Gatěk J, Melichar B.

Anal Bioanal Chem. 2015 Jan;407(3):991-1002. doi: 10.1007/s00216-014-8272-z. Epub 2014 Oct 29.

PMID:
25352274
18.

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial.

Élez E, Kocáková I, Höhler T, Martens UM, Bokemeyer C, Van Cutsem E, Melichar B, Smakal M, Csőszi T, Topuzov E, Orlova R, Tjulandin S, Rivera F, Straub J, Bruns R, Quaratino S, Tabernero J.

Ann Oncol. 2015 Jan;26(1):132-40. doi: 10.1093/annonc/mdu474. Epub 2014 Oct 15.

PMID:
25319061
19.

[Influence of preoperative chemoradiotherapy on changes of epidermal growth factor receptor expression in patients treated by preoperative chemoradiotherapy for local advanced rectal carcinoma].

Richter I, Dvořák J, Blüml A, Cermáková E, Bartoš J, Urbanec M, Sitorová V, Ryška A, Sirák I, Buka D, Ferko A, Melichar B, Petera J.

Klin Onkol. 2014;27(5):361-6. Czech.

PMID:
25312714
20.

Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry.

Kubackova K, Bortlicek Z, Pavlik T, Melichar B, Linke Z, Pokorna P, Vyzula R, Prausova J, Buchler T; on behalf of the Czech Renal Cancer Cooperative Group.

Target Oncol. 2014 Oct 12. [Epub ahead of print]

PMID:
25304882
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk